LAVA Therapeutics (NASDAQ:LVTX) Short Interest Down 20.9% in August

LAVA Therapeutics (NASDAQ:LVTX) was the target of a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 45,400 shares, a drop of 20.9% from the August 15th total of 57,400 shares. Based on an average daily volume of 69,300 shares, the short-interest ratio is currently 0.7 days. Currently, 0.3% of the company’s shares are sold short.

LAVA Therapeutics Stock Up 2.6 %

Shares of LVTX traded up $0.04 during mid-day trading on Tuesday, reaching $1.76. The company had a trading volume of 45,694 shares, compared to its average volume of 684,267. LAVA Therapeutics has a 52 week low of $1.13 and a 52 week high of $6.47. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.39 and a current ratio of 6.39. The firm has a 50-day moving average price of $1.86 and a 200 day moving average price of $2.37. The company has a market capitalization of $44.62 million, a price-to-earnings ratio of -1.63 and a beta of 0.51.

LAVA Therapeutics (NASDAQ:LVTX) last announced its earnings results on Tuesday, August 20th. The company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.05. LAVA Therapeutics had a negative return on equity of 48.53% and a negative net margin of 228.02%. On average, sell-side analysts forecast that LAVA Therapeutics will post -1.28 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in LAVA Therapeutics stock. Pathway Financial Advisors LLC acquired a new position in LAVA Therapeutics (NASDAQ:LVTX) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 14,000 shares of the company’s stock, valued at approximately $47,000.

Wall Street Analyst Weigh In

LVTX has been the topic of several recent analyst reports. JMP Securities reiterated a “market outperform” rating and set a $6.00 price target on shares of LAVA Therapeutics in a research report on Wednesday, August 21st. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of LAVA Therapeutics in a research report on Friday, June 28th.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.